Creatine Goes Cognitive: Inside a Real Trial in Mild Cognitive Impairment

The trial, listed on the U.S. clinical trial registry as NCT06948149, is the kind of design performance-science readers should recognize on sight: a 2×2 factorial that crosses a supplement (creatine vs. placebo) with an exercise mode (progressive resistance training vs. an active control of balance-and-tone classes). Four arms, one question: when an aging brain is already slipping, does the powder in the tub do anything on its own, does the barbell do anything on its own, and — the most interesting cell in the grid — do they do more together than apart?

For an audience used to thinking about creatine in milliseconds of phosphocreatine resynthesis, the cognitive framing requires a small mental gear shift. The neurons you are asking to remember a grocery list are not so different, energetically, from the type-II fibers you ask to clear a heavy single. Both run on ATP. Both can be bottlenecked when demand outruns supply. Creatine, in muscle, accelerates the recharge. The hypothesis under test here is whether the same chemistry helps in tissue that fires far more continuously and where the cost of an energy shortfall is measured not in a missed rep but in a missed name.

The case for taking creatine seriously in older brains rests on three pillars, none of them yet a load-bearing wall. The first is endogenous decline: creatine is naturally synthesized in the body and tissue stores fall with age, as the trial's own background notes. The second is the established benefit in older muscle and bone — creatine consistently shows up in the literature as a useful adjunct for lean mass and bone density when paired with training in older adults, the very substrate this trial is leveraging. The third, and the shakiest, is a thin but suggestive line of work hinting that creatine supplementation may nudge cognitive measures in older people, particularly under conditions of stress, sleep loss, or compromised baseline function.

That third pillar is exactly why an MCI cohort is the right place to push. Healthy young brains, like healthy young muscle, are creatine-replete and metabolically forgiving; an exogenous top-up has little headroom to work with. A brain operating with reduced reserve — the working definition of mild cognitive impairment — is the analogue of an athlete dropped into altitude. Supply constraints become visible. If creatine helps a brain anywhere, it should help here first.

The exercise arm matters just as much. Resistance training is one of the very few interventions with credible human evidence for improving cognition in older adults, and the trial's protocol doesn't cut corners: three 60-minute supervised sessions per week, progressive loading across major muscle groups, sustained over half a year. That is a real training stimulus, not a wellness gesture. The placebo-exercise arm — balance-and-tone classes — controls for the social, scheduling, and gentle-movement effects that any group exercise intervention inevitably carries, which is the kind of methodological hygiene that lets a result actually mean something.

The factorial structure is the elegant part. Comparing creatine-plus-training against placebo-plus-training isolates the creatine effect on top of a known cognitive intervention. Comparing creatine-plus-balance against placebo-plus-balance isolates creatine in the absence of meaningful loading — the closest this trial gets to asking whether a scoop a day, by itself, does anything for an MCI brain. And the contrast between the two combined arms tests for synergy: is the brain benefit of lifting amplified when the cell's energetic substrate is also topped up?

What the trial will not tell us, even at its best, is whether creatine prevents cognitive decline in people who do not yet have it, whether it changes long-term dementia trajectories, or whether a different dose, form, or duration would produce a different verdict. Twenty-six weeks is long enough to see meaningful cognitive change but short of the multi-year horizons on which neurodegeneration plays out. The outcomes — cognition, brain-health measures, and physical function — are appropriately broad, and the population is narrow on purpose. Read the eventual results as a sharply focused photograph, not a landscape.